← Eichor
Study identifier: NCT07544784 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

Condition: Colorectal Cancer Liver Metastases (CRLM)  ·  Sponsor: Fudan University

PhasePhase 2
Planned participants73
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, randomized controlled, single-center phase II clinical study. It aims to compare the efficacy of AK104 plus radiotherapy combined with standard therapy versus standard therapy as first-line treatment for liver metastases from metastatic colorectal cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Wenhua Li  ·  +86-021-64175590  ·  whliiris@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Wenhua LiShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07544784